Alexa Sevin Valentino
Alexa Sevin Valentino has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Jangus B. Whitner
PrimaryOne Health
3 shared publications - Erin E. Pauling
Clinical Associate Professor, Ambulatory Care, Binghamton University School of Pharmacy and Pharmaceutical Sciences, State University of New York, Binghamton, New York, USA
2 shared publications - Jennifer Lin Rodis
The Ohio State University College of Pharmacy, 500 W. 12(th) Ave., Columbus, OH 43210
2 shared publications - Junan Li
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio
2 shared publications Lisa A. Mueller
Community Health Network, Indianapolis, IN, USA
2 shared publications- Megan Ducker Coleman
Wingate University School of Pharmacy, 515 North Main Street, Wingate, NC 28174, United States
2 shared publications
Latest Publications
- 30 October 2025
- Published by SAGE Publications in Public Health Reports®
Pharmacist Involvement in Hepatitis C Management and Time to Treatment Initiation in Medically Underserved Primary Care Settings
Objectives: Although the existing literature highlights the success of pharmacist-led hepatitis C virus (HCV) treatment, the impact of these models on time to treatment initiation has not been studied. This study compared outcomes for HCV treatment using direct-acting antivirals (DAAs) in 2 groups: pharmacist-led programs in 5 federally qualified health centers in Ohio and an external cohort from an out-of-state academic medical center. We assessed the time to HCV treatment initiation, rates of DAA initiation, and sustained virologic response (SVR) rates. Methods: We conducted a retrospective cohort analysis using electronic health records and pharmacy claims for patients with HCV referred to pharmacists from November 2021 through December 2023. We collected data on demographic characteristics, pre-entry characteristics, treatment initiation rates, time to initiation, and cure rates. The treatment initiation rate included all patients referred to a pharmacy. We defined time to initiation as the period from pharmacy referral to the date of medication pickup. We defined cure as achieving SVR 12 weeks posttreatment (SVR12) and analyzed SVR12 rates in an intent-to-treat and per-protocol manner. We compared time to initiation with an external cohort median of 300 days. Results: Of 477 referred patients, 317 (66.5%) initiated DAAs. The mean (SD) time to treatment initiation was 63.7 (74.2) days, with a median of 37 days. Among the 212 patients completing SVR12 laboratory tests, 194 achieved cure, yielding a per-protocol SVR12 of 91.5% and an intent-to-treat SVR12 of 61.2%. Patients without (vs with) health insurance and with (vs without) a history of substance abuse had longer treatment delays. Conclusions: This study demonstrates the value of integrating pharmacists into HCV treatment teams to meet public health needs.
- 30 October 2025
- Published by SAGE Publications in Public Health Reports®
Pharmacist Involvement in Hepatitis C Management and Time to Treatment Initiation in Medically Underserved Primary Care Settings
Objectives: Although the existing literature highlights the success of pharmacist-led hepatitis C virus (HCV) treatment, the impact of these models on time to treatment initiation has not been studied. This study compared outcomes for HCV treatment using direct-acting antivirals (DAAs) in 2 groups: pharmacist-led programs in 5 federally qualified health centers in Ohio and an external cohort from an out-of-state academic medical center. We assessed the time to HCV treatment initiation, rates of DAA initiation, and sustained virologic response (SVR) rates. Methods: We conducted a retrospective cohort analysis using electronic health records and pharmacy claims for patients with HCV referred to pharmacists from November 2021 through December 2023. We collected data on demographic characteristics, pre-entry characteristics, treatment initiation rates, time to initiation, and cure rates. The treatment initiation rate included all patients referred to a pharmacy. We defined time to initiation as the period from pharmacy referral to the date of medication pickup. We defined cure as achieving SVR 12 weeks posttreatment (SVR12) and analyzed SVR12 rates in an intent-to-treat and per-protocol manner. We compared time to initiation with an external cohort median of 300 days. Results: Of 477 referred patients, 317 (66.5%) initiated DAAs. The mean (SD) time to treatment initiation was 63.7 (74.2) days, with a median of 37 days. Among the 212 patients completing SVR12 laboratory tests, 194 achieved cure, yielding a per-protocol SVR12 of 91.5% and an intent-to-treat SVR12 of 61.2%. Patients without (vs with) health insurance and with (vs without) a history of substance abuse had longer treatment delays. Conclusions: This study demonstrates the value of integrating pharmacists into HCV treatment teams to meet public health needs.
- Open Access
- 28 August 2023
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 14 (3) , 8
Community Health Center 340B Program: A Qualitative Study of the Experiences of Patients with Diabetes
Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy is an academic, peer reviewed, open-access journal. Sponsored by U of MN College of Pharmacy Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy. A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, review articles, and student projects that focus on leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy.
- 28 August 2023
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 14 (3) , 8
Open AccessCommunity Health Center 340B Program: A Qualitative Study of the Experiences of Patients with Diabetes
Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy is an academic, peer reviewed, open-access journal. Sponsored by U of MN College of Pharmacy Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy. A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, review articles, and student projects that focus on leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy.
- 16 July 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (6) , 1891-1896.e2
Pharmacist-led telehealth tobacco cessation services compared with usual care in a community health center
- 16 July 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (6) , 1891-1896.e2
Pharmacist-led telehealth tobacco cessation services compared with usual care in a community health center
- 7 May 2022
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 14 (5) , 686-695
A team-led remote ambulatory care rotation: Creating efficiency without sacrificing quality
- 7 May 2022
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 14 (5) , 686-695
A team-led remote ambulatory care rotation: Creating efficiency without sacrificing quality
- 19 January 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (3) , 685-692
Using the Pharmacists’ Patient Care Process to address social determinants of health in patients with diabetes
- 19 January 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (3) , 685-692
Using the Pharmacists’ Patient Care Process to address social determinants of health in patients with diabetes
- 19 January 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (3) , 693-696
Collaborating with pharmacists to advance health equity for patients with diabetes through communication
- 19 January 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (3) , 693-696
Collaborating with pharmacists to advance health equity for patients with diabetes through communication
- Open Access
- 1 August 2021
- Published by Taylor & Francis in Integrated Pharmacy Research and Practice
- Vol. ume 10, 93-111
Pharmacist Provided Spirometry Services: A Scoping Review
Purpose: Despite international guidelines’ recommendations, spirometry is underutilized in the diagnosis and management of asthma and COPD. Spirometry may be an opportunity for trained pharmacists to meet the needs of patients with suspected or diagnosed lung conditions. The aim of this scoping review is to describe the literature including pharmacist provided spirometry services, specifically to identify: 1) the models of pharmacist provided spirometry services, and additional services commonly offered alongside spirometry, 2) pharmacist training and capability to obtain quality results, and (3) pharmacist, physician, and patient perspectives. Methods: In September 2020, a comprehensive literature search in PubMed and EMBASE was conducted to identify all relevant literature on the topic of pharmacist provided spirometry services using the search term: “pharmacist or pharmacy” and “spirometry or pulmonary function test or lung function test.” Literature was screened using inclusion/exclusion criteria and selected articles were charted and analyzed using the themes above. Results: A total of 27 records were included. The scoping review found that pharmacist provided spirometry has been conducted around the world in community pharmacies and clinic settings. Community pharmacists may increase access to spirometry screening; the lack of communication with primary care providers and remuneration are barriers that need to be overcome to optimize the utility of the service. Clinic-based services are interprofessional and collaborative, allowing a patient to receive the test, results, diagnosis, and medication changes in one visit. Following comprehensive training, pharmacists felt confident in their ability to perform spirometry and met quality standards at acceptable rates. Conclusion: Spirometry is an opportunity for pharmacists to improve evidence-based practice for screening and diagnosing lung conditions along with providing comprehensive services to complement testing. Data around provider and patient perspectives is limited and should be further investigated to determine if providers and patients would value and collaborate with pharmacists providing spirometry services.
- 1 August 2021
- Published by Taylor & Francis in Integrated Pharmacy Research and Practice
- Vol. ume 10, 93-111
Open AccessPharmacist Provided Spirometry Services: A Scoping Review
Purpose: Despite international guidelines’ recommendations, spirometry is underutilized in the diagnosis and management of asthma and COPD. Spirometry may be an opportunity for trained pharmacists to meet the needs of patients with suspected or diagnosed lung conditions. The aim of this scoping review is to describe the literature including pharmacist provided spirometry services, specifically to identify: 1) the models of pharmacist provided spirometry services, and additional services commonly offered alongside spirometry, 2) pharmacist training and capability to obtain quality results, and (3) pharmacist, physician, and patient perspectives. Methods: In September 2020, a comprehensive literature search in PubMed and EMBASE was conducted to identify all relevant literature on the topic of pharmacist provided spirometry services using the search term: “pharmacist or pharmacy” and “spirometry or pulmonary function test or lung function test.” Literature was screened using inclusion/exclusion criteria and selected articles were charted and analyzed using the themes above. Results: A total of 27 records were included. The scoping review found that pharmacist provided spirometry has been conducted around the world in community pharmacies and clinic settings. Community pharmacists may increase access to spirometry screening; the lack of communication with primary care providers and remuneration are barriers that need to be overcome to optimize the utility of the service. Clinic-based services are interprofessional and collaborative, allowing a patient to receive the test, results, diagnosis, and medication changes in one visit. Following comprehensive training, pharmacists felt confident in their ability to perform spirometry and met quality standards at acceptable rates. Conclusion: Spirometry is an opportunity for pharmacists to improve evidence-based practice for screening and diagnosing lung conditions along with providing comprehensive services to complement testing. Data around provider and patient perspectives is limited and should be further investigated to determine if providers and patients would value and collaborate with pharmacists providing spirometry services.
- 1 November 2019
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 11 (11) , 1190-1195
A team-based learning approach to interprofessional education of medical and pharmacy students
- 1 November 2019
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 11 (11) , 1190-1195
A team-based learning approach to interprofessional education of medical and pharmacy students